Primary Prevention of Cardiovascular Risk in Lithuania—Results from EUROASPIRE V Survey
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background and Objectives: Cardiovascular disease (CVD) prevention guidelines define targets for lifestyle and risk factors for patients at high risk of developing CVD. We assessed the control of these factors, as well as CVD risk perception in patients enrolled into the primary care arm of the European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE V) survey in Lithuania. Materials and Methods: Data were collected as the part of the EUROASPIRE V survey, a multicenter, prospective, cross-sectional observational study. Adults without a documented CVD who had been prescribed antihypertensive medicines and/or lipid-lowering medicines and/or treatment for diabetes (diet and/oral antidiabetic medicines and/or insulin) were eligible for the survey. Data were collected through the review of medical records, patients’ interview, physical examination and laboratory tests. Results: A total of 201 patients were enrolled. Very few patients reached targets for low-density lipoprotein cholesterol (LDL-C) (4.5%), waist circumference (17.4%) and body mass index (15.4%). Only 31% of very high CVD risk patients and 52% of high-risk patients used statins. Blood pressure target was achieved by 115 (57.2%) patients. Only 21.7% of patients at very high actual CVD risk and 27% patients at high risk correctly estimated their risk. Of patients at moderate actual CVD risk, 37.5% patients accurately self-assessed the risk. About 60%–80% of patients reported efforts to reduce the intake of sugar, salt or alcohol; more than 70% of patients were current nonsmokers. Only a third of patients reported weight reduction efforts (33.3%) or regular physical activity (27.4%). Conclusions: The control of cardiovascular risk factors in a selected group of primary prevention patients was unsatisfactory, especially in terms of LDL-C level and body weight parameters. Many patients did not accurately perceive their own risk of developing CVD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other studies found that factors such as age, gender, ethnicity, economic status, risk profile of patients, dose and intensity of statins, and study location may also influence statin adherence.20,82,83”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2020-3826 · Cited by 325
Updated review on the benefits of weight loss
Vidal, J. (2002) · International Journal of Obesity · doi:10.1038/sj.ijo.0802215 · Cited by 188
Halcox, J. P., Banegas, J. R., Roy, C., Dallongeville, J., De Backer, G., Guallar, E., Perk, J., Hajage, D., Henriksson, K. M., & Borghi, C. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-017-0591-5 · Cited by 122
Research works printed but not linked: 50
- Roth, 2018, Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: A systematic analysis for the Global Burden of Disease Study 2017, Lancet, 392, 1736, 10.1016/S0140-6736(18)32203-7 · DOI · Paper page
- Wong, 2014, Epidemiological studies of CHD and the evolution of preventive cardiology, Nat. Rev. Cardiol., 11, 276, 10.1038/nrcardio.2014.26 · DOI · Paper page
- Townsend, 2016, Cardiovascular disease in Europe: Epidemiological update 2016, Eur. Heart J., 37, 3232, 10.1093/eurheartj/ehw334 · DOI · Paper page
- Di Girolamo, C., Nusselder, W.J., Bopp, M., Bronnum-Hansen, H., Costa, G., Kovacs, K., Leinsalu, M., Martikainen, P., Pacelli, B., and Rubio Valverde, J. (2019). Progress in reducing inequalities in cardiovascular disease mortality in Europe. Heart. · DOI
- Ezzati, 2015, Contributions of risk factors and medical care to cardiovascular mortality trends, Nat. Rev. Cardiol., 12, 508, 10.1038/nrcardio.2015.82 · DOI · Paper page
- Piepoli, 2016, 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR), Eur. Heart J., 37, 2315, 10.1093/eurheartj/ehw106 · DOI · Paper page
- Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent, C., Blackwell, L., Emberson, J., Holland, L., Reith, C., Bhala, N., Peto, R., Barnes, E., and Keech, A. (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 376, 1670–1681. · DOI · Paper page
- Sabatine, M.S., Wiviott, S.D., Im, K., Murphy, S.A., and Giugliano, R.P. (2018). Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels. JAMA Cardiol., 3. · DOI · Paper page
- Lewington, 2002, Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies, Lancet, 360, 1903, 10.1016/S0140-6736(02)11911-8 · DOI · Paper page
- Turnbull, 2008, Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: Meta-analysis of randomised trials, BMJ, 336, 1121, 10.1136/bmj.39548.738368.BE · DOI · Paper page
- Jousilahti, 2016, Primary prevention and risk factor reduction in coronary heart disease mortality among working aged men and women in eastern Finland over 40 years: Population based observational study, BMJ, 352, i721, 10.1136/bmj.i721 · DOI · Paper page
- Sarwar, 2010, Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies, Lancet, 375, 2215, 10.1016/S0140-6736(10)60484-9 · DOI · Paper page
- Weiss, 2009, Impact of glycemic treatment choices on cardiovascular complications in type 2 diabetes, Cardiol. Rev., 17, 165, 10.1097/CRD.0b013e3181a7b34c · DOI
- Canto, 2003, Major risk factors for cardiovascular disease: Debunking the “only 50%” myth, JAMA, 290, 947, 10.1001/jama.290.7.947 · DOI
- NCEP Expert Panel (2002). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 106, 3143–3421. · DOI · Paper page
- Mottillo, 2010, The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis, J. Am. Coll Cardiol., 56, 1113, 10.1016/j.jacc.2010.05.034 · DOI · Paper page
- Calugi, 2010, Lifestyle modification in the management of the metabolic syndrome: Achievements and challenges, Diabetes Metab. Syndr. Obes., 3, 373, 10.2147/DMSO.S13860 · DOI
- Goldstein, 1992, Beneficial health effects of modest weight loss, Int. J. Obes. Relat. Metab., 16, 397
- Kotseva, 2017, The EUROASPIRE surveys: Lessons learned in cardiovascular disease prevention, Cardiovasc. Diagn. Ther., 7, 633, 10.21037/cdt.2017.04.06 · DOI · Paper page
- Williams, 2018, 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension, J. Hypertens., 36, 1953, 10.1097/HJH.0000000000001940 · DOI · Paper page
- Aguilar-Palacio, I., Malo, S., Feja, C., Lallana, M., Leon-Latre, M., Casasnovas, J.A., Rabanaque, M., and Guallar, E. (2018). Risk factors control for primary prevention of cardiovascular disease in men: Evidence from the Aragon Workers Health Study (AWHS). PLoS ONE, 13. · DOI
- Banegas, 2011, Achievement of lipoprotein goals among patients with metabolic syndrome at high cardiovascular risk across Europe. The EURIKA study, Eur. Heart J., 32, 2098
- Blom, D.J., Santos, R.D., Daclin, V., Mercier, F., Ruiz, A.J., Danchin, N., and ICLPS Study Group (2019). The challenge of multiple cardiovascular risk factor control outside Western Europe: Findings from the International ChoLesterol management Practice Study. Eur. J. Prev. Cardiol. · DOI
- Figliuzzi, 2018, Achievement of multiple therapeutic targets for cardiovascular disease prevention: Retrospective analysis of real practice in Italy, Clin. Cardiol., 41, 788, 10.1002/clc.22955 · DOI
- Presta, 2019, Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy, Atherosclerosis, 285, 40, 10.1016/j.atherosclerosis.2019.03.017 · DOI · Paper page
- Catapano, 2016, 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias, Eur. Heart J., 37, 2999, 10.1093/eurheartj/ehw272 · DOI · Paper page
- Taylor, F., Huffman, M.D., Macedo, A.F., Moore, T.H., Burke, M., Davey Smith, G., Ward, K., and Ebrahim, S. (2013). Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst. Rev. · DOI · Paper page
- Karmali, 2016, Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An Overview of Systematic Reviews, JAMA Cardiol., 1, 341, 10.1001/jamacardio.2016.0218 · DOI · Paper page
- Halcox, J.P., Tubach, F., Lopez-Garcia, E., De Backer, G., Borghi, C., Dallongeville, J., Guallar, E., Medina, J., Perk, J., and Sazova, O. (2015). Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular disease across Europe. PLoS ONE, 10. · DOI
- Homer, 2015, Statin prescribing for primary prevention of cardiovascular disease: A cross-sectional, observational study, Br. J. Gen. Pract., 65, e538, 10.3399/bjgp15X686113 · DOI
- Ueda, P., Lung, T.W., Lu, Y., Salomon, J.A., Rahimi, K., Clarke, P., and Danaei, G. (2018). Treatment gaps and potential cardiovascular risk reduction from expanded statin use in the US and England. PLoS ONE, 13. · DOI
- Roccatagliata, 2006, Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients’ risk level, Vasc. Health Risk Manag., 2, 507, 10.2147/vhrm.2006.2.4.507 · DOI
- Turner, G.M., Calvert, M., Feltham, M.G., Ryan, R., Fitzmaurice, D., Cheng, K.K., and Marshall, T. (2016). Under-prescribing of Prevention Drugs and Primary Prevention of Stroke and Transient Ischaemic Attack in UK General Practice: A Retrospective Analysis. PLoS Med., 13. · DOI
- Kotseva, 2016, Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions, Eur. J. Prev. Cardiol., 23, 2007, 10.1177/2047487316667784 · DOI · Paper page
- Byrne, 2019, Statins for the primary prevention of cardiovascular disease: An overview of systematic reviews, BMJ Open, 9, e023085, 10.1136/bmjopen-2018-023085 · DOI · Paper page
- Kedward, 2003, A qualitative study of barriers to the use of statins and the implementation of coronary heart disease prevention in primary care, Br. J. Gen. Pract., 53, 684
- Casula, 2012, Adherence to lipid-lowering treatment: The patient perspective, Patient Prefer. Adherence, 6, 805
- Fung, V., Graetz, I., Reed, M., and Jaffe, M.G. (2018). Patient-reported adherence to statin therapy, barriers to adherence, and perceptions of cardiovascular risk. PLoS ONE, 13. · DOI · Paper page
- Ju, 2018, Patient beliefs and attitudes to taking statins: Systematic review of qualitative studies, Br. J. Gen. Pract., 68, e408, 10.3399/bjgp18X696365 · DOI
- Vinogradova, 2016, Discontinuation and restarting in patients on statin treatment: Prospective open cohort study using a primary care database, BMJ, 353, i3305, 10.1136/bmj.i3305 · DOI · Paper page
- Hope, H.F., Binkley, G.M., Fenton, S., Kitas, G.D., Verstappen, S.M.M., and Symmons, D.P.M. (2019). Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease. PLoS ONE, 14. · DOI · Paper page
- Naderi, S.H., Bestwick, J.P., and Wald, D.S. (2012). Adherence to drugs that prevent cardiovascular disease: Meta-analysis on 376,162 patients. Am. J. Med., 125. · DOI · Paper page
- Qadi, 2019, Patients’ and health professionals’ attitudes and perceptions towards the initiation of preventive drugs for primary prevention of cardiovascular disease: Protocol for a systematic review of qualitative studies, BMJ Open, 9, e025587, 10.1136/bmjopen-2018-025587 · DOI
- Brawarsky, P., Eibensteiner, K., Klinger, E.V., Baer, H.J., Getty, G., Orav, E.J., Colditz, G., and Haas, J.S. (2018). Accuracy of self-perceived risk for common conditions. Cogent Med., 5. · DOI
- Helou, 2018, Association between clinical factors and self-underestimation of cardiovascular risk in subjects submitted to a routine health evaluation, Clin. Cardiol., 41, 28, 10.1002/clc.22841 · DOI
- Alwan, 2009, Perception of cardiovascular risk and comparison with actual cardiovascular risk, Eur. J. Cardiovasc. Prev. Rehabil., 16, 556, 10.1097/HJR.0b013e32832d194d · doi:10.1097/hjr.0b013e32832d194d
- Katz, 2015, Calculated and perceived cardiovascular risk in asymptomatic subjects submitted to a routine medical evaluation: The perception gap, Eur. J. Prev. Cardiol., 22, 1076, 10.1177/2047487314543074 · DOI
- Lee, 2019, The relationship between psychological states and health perception in individuals at risk for cardiovascular disease, Psychol. Res. Behav. Manag., 12, 317, 10.2147/PRBM.S198280 · DOI
- Desgraz, 2017, Comparison of self-perceived cardiovascular disease risk among smokers with Framingham and PROCAM scores: A cross-sectional analysis of baseline data from a randomised controlled trial, BMJ Open, 7, e012063, 10.1136/bmjopen-2016-012063 · DOI
- Petr, 2014, Perceived lifetime risk for cardiovascular disease (from the Dallas Heart Study), Am. J. Cardiol., 114, 53, 10.1016/j.amjcard.2014.04.006 · DOI
Cited by
Rakhshanda, S., Briggs, N. E., Rhee, J., Rye, K.-A., Liaw, S.-T., & Jonnagaddala, J. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag175 · Cited by 6
Metadata
- Authors
- Urbonas, G., Vencevičienė, L., Valius, L., Krivickienė, I., Petrauskas, L., Lazarenkienė, G., Karpavičienė, J., Briedė, G., Žučenkienė, E., & Vencevičius, K.
- Affiliations
- Department of Family Medicine, Medical Academy, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania
- Institute of Clinical Medicine, Clinic of Internal Diseases, Family Medicine and Oncology, Faculty of Medicine, Vilnius University, 01513 Vilnius, Lithuania
- ORCID
- Urbonas, Gediminas
- Venue
- Medicina
- Publisher
- MDPI AG
- Published
- 2020-03-18
- Volume
- 56
- Issue
- 3
- Pages
- 134
- ISSN
- 1648-9144
- Cited by
- 4
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Primary Prevention of Cardiovascular Risk in Lithuania—Results from EUROASPIRE V Survey. https://app.cochat.ai/papers/10.3390/medicina56030134
- The paper
- Urbonas, G., Vencevičienė, L., Valius, L., Krivickienė, I., Petrauskas, L., Lazarenkienė, G., Karpavičienė, J., Briedė, G., Žučenkienė, E., & Vencevičius, K. (2020). Primary Prevention of Cardiovascular Risk in Lithuania—Results from EUROASPIRE V Survey. Medicina. https://doi.org/10.3390/medicina56030134
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.